Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 50090-6438

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 50090-6438). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906438)

Lurasidone hydrochloride 20 mg film-coated tablets packaging label from A-S Medication Solutions. The label states that each film-coated tablet contains lurasidone hydrochloride 20 mg. It advises storing the product at 77 degrees Fahrenheit and indicates a quantity of 30 tablets in the package. The label includes the NDC 50090-6438-0 and a QR code for dosage information.*

FDA Label Image

Figure 1 (Lurasidone Fig1)

A dot plot chart depicting the impact of various interacting drugs on the pharmacokinetics (PK) of lurasidone. The x-axis shows fold change relative to lurasidone alone, ranging from -4 to 4, and the y-axis lists interacting drugs categorized as strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors, and strong CYP3A4 inducers. Data points with 90% confidence intervals represent changes in Cmax and AUC values for lurasidone when co-administered with ketoconazole, diltiazem, rifampin, and lithium.*

FDA Label Image

Figure 2 (Lurasidone Fig2)

A chart showing the pharmacokinetic interactions of various drugs with fold change and 90% confidence intervals. The x-axis represents change relative to the interacting drug alone, and the y-axis lists interacting drugs including digoxin, midazolam, oral contraceptives (ethinyl estradiol and norelgestromin), and lithium. The parameters measured include Cmax, AUC, and trough values, depicted with data points and error bars for each drug and parameter.*

FDA Label Image

Figure 3 (Lurasidone Fig3)

Pharmacokinetic (PK) chart illustrating fold change and 90% confidence intervals for lurasidone hydrochloride across different conditions including renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population factors such as gender and race. The x-axis shows change relative to reference values for parameters Cmax and AUC, with data points and error bars visualizing variability under each condition.*

FDA Label Image

Chemical Structure (Lurasidone Str)

Chemical structure of lurasidone hydrochloride showing its molecular framework with rings and functional groups, including a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.